FLIXOTIDE ® Fluticasone

FLIXOTIDE ® is a drug based on Fluticasone propionate

THERAPEUTIC GROUP: Drugs for obstructive airway disorders

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications FLIXOTIDE ® Fluticasone

FLIXOTIDE ® is indicated in the control of the evolution of the asthmatic disease and in the treatment of obstructive airway disorders such as the conditions of bronchostenosis.

Mechanism of action FLIXOTIDE ® Fluticasone

FLIXOTIDE ® is a medicinal specialty particularly used in the clinical setting for its marked anti-inflammatory and partially antiallergic activities.

These therapeutic properties are due to the presence of its active ingredient Fluticasone propionate, a synthetic corticosteroid with an intense anti-inflammatory activity, even superior to that of Beclometasone, capable of reducing the local inflammatory level, controlling the secretion of cytokines, prostaglandins and leukotrienes.

The anti-inflammatory action is also associated with the anti-allergic action, which is important in reducing the degree of activation of the pulmonary mast cells, determining among other things a significant reduction in the obstructive symptomatology induced by the congestion of the nasal mucosa, due to the intense vasodilation that is observed in these contexts .

All this is accompanied by advantageous pharmacokinetic properties, which make therapy safe, minimizing the risk of developing systemic adverse reactions.

Studies carried out and clinical efficacy

FLUTICASONE AND DELIVERY SYSTEMS

J Clin Diagn Res. 2013 Sep; 7 (9): 1908-12. doi: 10.7860 / JCDR / 2013 / 6705.3348. Epub 2013 Sep 10.

Kolasani BP, Lanke VM, Diyya S.

Study that tests the effectiveness of Fluticasone taken through different inhalation systems, demonstrating the same therapeutic efficacy of the drug regardless of the delivery system in patients with chronic stable bronchial asthma

FLUTICASONE IN SINGLE-ADMINISTRATION

Eur Respir J. 2013 Oct 17. [Epub ahead of print]

O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, Jacques L, LÃ¶tvall J.

de Aguiar MM, from Silva HJ, Rizzo JA, Leite DF, Silva Lima ME, Sarinho ES.

Interesting work that shows how the daily administration of Fluticasone is useful and effective in the treatment of asthma, greatly improving the ventilatory capacities and patient compliance.

FLUTICASONE AND FORMETEROL IN COMBINED THERAPY

Clin Ther. 2013 Jul; 35 (7): 950-66. doi: 10.1016 / j.clinthera.2013.05.012.

Pearlman DS, LaForce CF, Kaiser K.

Study demonstrating that the combined treatment between Fluticasone and Formeterol presents a good tolerability and a decidedly greater efficacy compared to the monotherapies, in adolescents and adults suffering from asthma.

Method of use and dosage

FLIXOTIDE ®

Inhalation powder from 100, 250 and 500 mcg of Fluticasone propionate.

Pressurized inhalation suspension from 50, 125, 250 mcg of Fluticasone propionate.

The choice of the therapeutic scheme, the timing of recruitment and the pharmaceutical format to be used is up to the doctor after having carefully evaluated the patient's general health conditions and the severity of his clinical picture.

The dosage formulation must therefore be adapted from patient to patient, however considering in adults as a standard dose the daily 200 mcg of Fluticasone propionate in two different administrations.

Warnings FLIXOTIDE ® Fluticasone

FLIXOTIDE ® therapy should be preceded by a careful medical examination in order to clarify the patient's clinical picture and the consequent prescription appropriateness of the drug.

It should be remembered that in some cases combined therapy with Beta 2 agonists could be indicated in order to further improve ventilatory capacities especially in the case of acute asthmatic attacks, for which Fluticasone is not very useful.

The patient should also consider how the prolonged treatment with corticosteroids can determine the onset of hypersensitivity reactions to the drug, sometimes even serious, to such an extent that it requires the immediate suspension of the drug.

Any overlap of bacterial infections of the upper respiratory tract should be treated with adequate antibiotic therapy.

It should be remembered that the use of Corticosteroids, without clinical necessity, is prohibited in and out of the race.

It is recommended to keep the medicine out of the reach of children.

FLIXOTIDE ® contains lactose, therefore patients with galactose intolerance, lactase enzyme deficiency and glucose-galactose malabsorption syndrome may develop further adverse reactions.

PREGNANCY AND BREASTFEEDING

Given the absence of significant clinical trials able to better characterize the safety profile of Fluticasone for the health of the fetus and infant, it would be appropriate to extend the aforementioned contraindications to the use of FLIXOTIDE ® also to pregnancy and the subsequent period of breastfeeding at the breast.

Interactions

Pharmacological interactions worthy of note are not known at the moment, although the simultaneous intake of inhibitors or inducers of the cytochromial system would be able to alter the pharmacokinetic characteristics of the possible quota of Fluticasone absorbed.

Contraindications FLIXOTIDE ® Fluticasone

The use of FLIXOTIDE ® is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients, in patients suffering from active or quiescent viral and tuberculosis infections and in pregnant and lactating women.

Undesirable effects - Side effects

FLIXOTIDE ® therapy, especially if it lasts for a long time, could cause local reactions such as candidiasis of the mouth and throat, cough and hoarseness.

Fortunately the systemic adverse reactions typical of corticosteroids worthy of clinical note are rarer.